Sunday, May 29, 2022
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Indian Drug Firms Recall Various Products In Us Market

Indian drug firms recall various products in US market

By PTI
Published: Published Date - 07:29 PM, Sun - 15 November 20
As per the USFDA, Marksans Pharma is recalling close to six lakh bottles of diabetes drug Metformin Hydrochloride extended-release tablets in strengths of 500 mg and 750 mg in the US market As per the USFDA, Marksans Pharma is recalling close to six lakh bottles of diabetes drug Metformin Hydrochloride extended-release tablets in strengths of 500 mg and 750 mg in the US market

New Delhi: Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Marksans Pharma is recalling diabetes drug, Zydus Pharmaceuticals (USA) is recalling drug which is used to reduce stomach acid.

Similarly, Aurobindo Pharma (USA) is recalling pain relieving drug, while Jubilant Cadista is recalling a medication used to treat schizophrenia. As per the USFDA, Marksans Pharma is recalling close to six lakh bottles of diabetes drug Metformin Hydrochloride extended-release tablets in strengths of 500 mg and 750 mg in the US market. The medication lot has been manufactured at the company’s Goa-based manufacturing facility. As per the USFDA, the company is recalling the product due to deviation from the current good manufacturing practices (CGMP).

“FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level,” it noted. NDMA has been defined as a probable human carcinogen. Metformin Hydrochloride extended-release tablet is a prescription oral medication indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type-2 diabetes mellitus.
Various companies across the globe have announced similar recalls for the product after the USFDA pointed out presence of NDMA above permissible limits. FDA’s testing has shown elevated levels of NDMA in some extended release (ER) metformin formulation, but not in the immediate release (IR) formulation or in the active pharmaceutical ingredient.

NDMA is classified as a probable human carcinogen based on results from laboratory tests. It is a known environmental contaminant and found in water and food, including meats, dairy products and vegetables. Further, the USFDA said Zydus Pharmaceuticals (USA) is recalling  14,748 cartons of Lansoprazole delayed-release orally disintegrating tablets due to failed dissolution specification. The product has been manufactured by Ahmedabad-based Cadila Healthcare. The USFDA has classified the initiatives taken by Marksans and Zydus as class II recalls.

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Further, the US health regulator said Aurobindo Pharma USA is recalling 7,440 bottles of Ibuprofen oral suspension drug for labelling error.

Besides, Jubilant Cadista Pharmaceuticals, Inc is recalling 23,616 blister packs of Olanzapine orally disintegrating tablets for being “subpotent”, the USFDA noted.

The recalled lot has been produced by Roorkee-based (Uttarakhand) Jubilant Generics. The US health regulator classified both the recalls as class III. As per the USFDA, a class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

  • Follow Us :
  • Tags
  • Aurobindo Pharma
  • CGMP
  • diabetes mellitus
  • Indian drug firms

Related News

  • Supreme Court fixes 60 day window to claim for Covid death compensation

  • Aurobindo Pharma acquires domestic formulations business of Veritaz Healthcare

  • Three Hyderabad firms to make generic version of Pfizer’s Covid drug

  • BE prices Corbevax at Rs 145 for Government, Rs 800 for private players

  • ‘Regulatory harmonisation critical to enhance pharma innovation, compliance’

  • Telangana: 95 cr worth of works at MNJ Cancer Hospital for quality care

Latest News

  • India commences groundwork for 5G spectrum auction, to introduce services by 2022-23

    11 mins ago
  • FPI sell-off continues; pull out Rs 39,000 cr from equities in May so far

    19 mins ago
  • ‘Top Gun: Maverick’ jets off to $150 million Memorial Day opening

    26 mins ago
  • PM Modi hails Andhra man for donating his retirement benefits for education of girls

    27 mins ago
  • Twitter has very ‘bot-friendly’ rules, says Elon Musk

    41 mins ago
  • India belongs to Dravidians and Adivasis, not Thackeray or Modi: Owaisi

    43 mins ago
  • ‘Adopt Yoga in daily life’: PM Modi’s mantra in ‘Mann Ki Baat’

    56 mins ago
  • It’s ruthless business for me on field; Nehra gets best out of me: Hardik Pandya

    58 mins ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam